My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Daiichi Sankyo Ltd (OP:DSKYF)

20.40 +0.15 (+0.74%)

Streaming Delayed Price Updated: 1:53 PM EST, Jan 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Daiichi Sankyo Ltd

< Previous 1 2 Next >

The Post-Keytruda Pivot: Inside Merck’s Strategic Evolution and the RVMD Landscape

Today 10:27 EST

As of January 26, 2026, Merck & Co. (NYSE: MRK) stands at the most critical juncture in its 135-year history. Known globally for its dominant oncology franchise and robust vaccine portfolio, the...

Via Finterra

FDA Approves AstraZeneca And Daiichi Sankyo's Datroway For EGFR-Mutated Lung Cancer ↗

June 24, 2025

FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response rate and a $45 million milestone due.

Via Benzinga

AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients ↗

April 21, 2025

AstraZeneca's Enhertu combo improved progression-free survival in HER2+ metastatic breast cancer in a Phase 3 trial, showing promising early results.

Via Benzinga

Daiichi, Zymeworks Terminate Seven Year-Cancer Antibody Pact ↗

March 20, 2023

Via Benzinga

Daiichi Sankyo Seeks Approval In Japan For Its mRNA-Based COVID-19 Vaccine ↗

January 13, 2023

Via Benzinga

FDA Approves AstraZeneca, Daiichi Sankyo's Enhertu For Certain Type Of Breast Cancer Patients ↗

January 28, 2025

FDA approves Enhertu for metastatic breast cancer with HER2-low or HER2-ultralow expression after showing significant efficacy in the DESTINY-Breast06 trial.

Via Benzinga

FDA Approves AstraZeneca's Datroway For Pretreated Breast Cancer Patients ↗

January 21, 2025

AstraZeneca's Datroway gains FDA approval for HR-positive, HER2-negative breast cancer after prior therapies, based on Phase 3 trial data.

Via Benzinga

After Lung Cancer Approval, AstraZeneca's Imfinzi Goes Under FDA Priority Review For Bladder Cancer ↗

December 06, 2024

AstraZeneca's Imfinzi gains FDA Priority Review for bladder cancer. Key trial data shows improved survival and progression outcomes in treated patients.

Via Benzinga

Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients ↗

September 23, 2024

AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically significant improvement in overall survival. The trial met its progression-free...

Via Benzinga

AstraZeneca's Investigational Cancer Drug Disappoints In Late-Stage Lung Cancer Trial ↗

September 10, 2024

AstraZeneca shared detailed results from the TROPION-Lung01 Phase 3 trial of datopotamab deruxtecan for non-small cell lung cancer, showing a clinically meaningful trend in overall survival compared to...

Via Benzinga

Week In Review: Curon Out-Licenses T-Cell-Engager To Merck For $700 Million Upfront ↗

August 10, 2024

Curon Biopharmaceutical, a Shanghai company, out-licensed global rights for a clinical-stage bispecific candidate to Merck (MSD) for $700 million upfront plus $600 million in milestones.

Via Talk Markets

Recession-Resilient Asian Stock Picks: TSMC, SK Hynix Among This Analyst's Top 10 ↗

August 07, 2024

"As stock pickers, we focus on a basket of stocks that we believe will emerge from the current drawdown," strategists say.

Via Benzinga

Merck's Q2 Earnings: Revenue And EPS Beat Helped By Strong Keytruda Sales, But Acquisition Costs Bites Into Annual Profit Forecast ↗

July 30, 2024

Merck reports Q2 sales of $16.1 billion, a 7% increase YoY, beating estimates. Keytruda sales surged 16% to $7.27 billion. FDA approvals for Capvaxive and Winrevair highlight the quarter. Merck revises...

Via Benzinga

FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug ↗

June 27, 2024

The FDA issued a Complete Response Letter for Daiichi Sankyo and Merck's BLA for patritumab deruxtecan targeting EGFR-mutated NSCLC due to third-party manufacturing facility inspection findings. The...

Via Benzinga

5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More ↗

June 24, 2024

Biotech investing is risk-fraught but the returns could be staggering if one chooses to take the educated approach.

Via Benzinga

Why Is AstraZeneca Stock Trading Lower On Tuesday? ↗

May 28, 2024

AstraZeneca's TROPION-Lung01 phase 3 trial for datopotamab deruxtecan in NSCLC showed OS improvement in nonsquamous patients. While the overall trial did not reach statistical significance.

Via Benzinga

Double Good News For AstraZeneca's Breast Cancer Drugs ↗

April 29, 2024

Results from AstraZeneca's Enhertu trial vs. chemotherapy in HR-positive, HER2-low metastatic breast cancer.

Via Benzinga

AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor ↗

April 08, 2024

FDA approves Daiichi Sankyo's and AstraZeneca's Enhertu for unresectable or metastatic HER2+ solid tumors. Accelerated approval based on ORR and DOR. Boxed warnings for ILD/pneumonitis and embryo-fetal...

Via Benzinga

What's Going On With Pfizer Stock Today? ↗

January 25, 2024

Pfizer to announce Q4 2023 earnings on 30th Jan. Analysts project EPS loss of $(0.22) and $14.25B in revenues.

Via Benzinga

Merck Signs Multi-Billion Deal With Japan's Daiichi Sankyo For Cancer Therapy Drug Development ↗

October 20, 2023

Merck & Company, Inc. (NYSE: MRK) and Japan's Daiichi Sankyo Co. Ltd. (OTC: DSKYF) entered into a global development and commercialization agreement.

Via Benzinga

Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting ↗

September 22, 2023

AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OTC: DSKYF) (OTC:

Via Benzinga

AstraZeneca's Reinforces Hold In Lung Cancer Settings: Touts Promising Data From Three Trials ↗

September 11, 2023

Daiichi Sankyo (OTC: DSKYF) (OTC: DSNKY) and AstraZeneca plc (NASDAQ: AZN) released initial results from the TROPION-Lung04 phase 1b tria

Via Benzinga

FDA Greenlights Daiichi Sankyo's Blood Cancer Drug, A Promising Competitor to Novartis' Rydapt ↗

July 21, 2023

The FDA has approved Daiichi Sankyo's (OTC: DSNKY) Vanflyta (quizartinib) in

Via Benzinga

AstraZeneca Shares Under Pressure On Some Adverse Events In Late-Stage Lung Cancer Drug Trial ↗

July 03, 2023

AstraZeneca Plc (NASDAQ: AZN) reported high-level results from the TROPION-Lung01 Phase 3 trial of datopotamab deruxtecan (Dato-DXd) in patients with locally advanced or metastatic non-small cell lung...

Via Benzinga

AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting ↗

March 06, 2023

Via Benzinga

AstraZeneca - Daiichi Sankyo's Enhertu Wins European Approval For Gastric Cancer, CHMP Backs Other Cancer Drugs ↗

December 19, 2022

Via Benzinga

European Medicines Agency's Advisory Committee Backs Approval Of AstraZeneca's Three Cancer Drugs ↗

November 14, 2022

Via Benzinga

With Upcoming Contentious Meeting, This Analyst Cuts Price Target On Spectrum Pharma ↗

September 21, 2022

Via Benzinga

Seagen Suffers Loss In Arbitration Dispute Over ADC Technology ↗

August 15, 2022

Via Benzinga

AstraZeneca-Daiichi's Flagship Breast Cancer Drug Improves Survival In Late-Stage Study ↗

August 15, 2022

Via Benzinga

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.